Pharmacologic Modulation of Hippocampal Activity in Psychosis

No abstract is available for this paper.

• Publication year

  2020

• Venue

  Case Medical Research

• Publication date

  2020-02-20

• Fields of study

  Not labeled

• Identifiers
  DOI 10.31525/ct1-nct04277936
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Hyperactivity and Reduced Activation of Anterior Hippocampus in Early Psychosis.

  2019cited by this paper
• Antiepileptic Drug of Levetiracetam Decreases Centrotemporal Spike-Associated Activation in Rolandic Epilepsy

  2018cited by this paper
• Prefrontal GABA levels, hippocampal resting perfusion and the risk of psychosis

  2018cited by this paper
• Targeting neuronal dysfunction in schizophrenia with nicotine: Evidence from neurophysiology to neuroimaging

  2017cited by this paper
• Resting-state fMRI revealed different brain activities responding to valproic acid and levetiracetam in benign epilepsy with central-temporal spikes

  2017cited by this paper
• Population pharmacokinetics and dose-response relationship of levetiracetam in adult patients with epilepsy.

  2017cited by this paper
• Treatment with levetiracetam improves cognition in a ketamine rat model of schizophrenia.

  2017cited by this paper
• Adolescence as a period of vulnerability and intervention in schizophrenia: Insights from the MAM model.

  2016cited by this paper
• The role of integrin α(V)β(3) in osteocyte mechanotransduction.

  2015cited by this paper
• The adverse event profile of levetiracetam: A meta-analysis on children and adults.

  2015cited by this paper
• Tau-Dependent Kv4.2 Depletion and Dendritic Hyperexcitability in a Mouse Model of Alzheimer's Disease

  2015influential reference
• Structured Clinical Interview for the DSM (SCID)

  2015influential reference
• The antiepileptic drug levetiracetam improves auditory gating in DBA/2 mice

  2015influential reference
• Response of the medial temporal lobe network in amnestic mild cognitive impairment to therapeutic intervention assessed by fMRI and memory task performance

  2015influential reference
• GABAergic mechanisms of hippocampal hyperactivity in schizophrenia.

  2015cited by this paper
• New approaches to the management of schizophrenia: focus on aberrant hippocampal drive of dopamine pathways

  2014cited by this paper
• Levetiracetam reduces abnormal network activations in temporal lobe epilepsy

  2014cited by this paper
• Increased hippocampal CA1 cerebral blood volume in schizophrenia

  2014cited by this paper
• Magnetic resonance spectroscopy and tissue protein concentrations together suggest lower glutamate signaling in dentate gyrus in schizophrenia

  2014cited by this paper
• Neuroimaging biomarkers for early drug development in schizophrenia.

  2014cited by this paper
• Physiological Brain Activity Causes DNA Double Strand Breaks in Neurons — Exacerbation by Amyloid-β

  2013cited by this paper
• Effects of levetiracetam, an antiepileptic drug, on memory impairments associated with aging and Alzheimer's disease in mice.

  2013cited by this paper
• Dysconnectivity, large-scale networks and neuronal dynamics in schizophrenia.

  2013cited by this paper
• Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver.

  2013cited by this paper
• Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer’s disease model

  2012cited by this paper
• Stevens-Johnson syndrome induced by levetiracetam.

  2012cited by this paper
• Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment.

  2012influential reference
• Neural correlates of working memory in Temporal Lobe Epilepsy — An fMRI study

  2012cited by this paper
• Levetiracetam: a review of its use in epilepsy.

  2011influential reference
• Antagonism at serotonin 5-HT2A receptors modulates functional activity of frontohippocampal circuit

  2010cited by this paper
• Use of eye movement monitoring to examine item and relational memory in schizophrenia.

  2010cited by this paper
• Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications.

  2010cited by this paper
• Differential targeting of the CA1 subfield of the hippocampal formation by schizophrenia and related psychotic disorders.

  2009cited by this paper
• A Loss of Parvalbumin-Containing Interneurons Is Associated with Diminished Oscillatory Activity in an Animal Model of Schizophrenia

  2009cited by this paper
• Pharmacological stimulation of NMDA receptors via co-agonist site suppresses fMRI response to phencyclidine in the rat

  2008cited by this paper
• Monotherapy for partial epilepsy: focus on levetiracetam

  2008cited by this paper
• What we can do and what we cannot do with fMRI

  2008cited by this paper
• Neuronal Diversity and Temporal Dynamics: The Unity of Hippocampal Circuit Operations

  2008cited by this paper
• Treating schizophrenia symptoms with an α7 nicotinic agonist, from mice to men

  2007cited by this paper
• Interactions between Antiepileptic and Antipsychotic Drugs

  2006cited by this paper
• Assessment of a dose–response relationship of levetiracetam

  2006cited by this paper
• Long‐lasting Antiepileptic Effects of Levetiracetam against Epileptic Seizures in the Spontaneously Epileptic Rat (SER): Differentiation of Levetiracetam from Conventional Antiepileptic Drugs

  2005cited by this paper
• Levetiracetam in the Treatment of Status epilepticus in Adults: A Study of 13 Episodes

  2005cited by this paper
• A Systematic Review of the Prevalence of Schizophrenia

  2005influential reference
• Review of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia.

  2005cited by this paper
• The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.

  2004cited by this paper
• Practice Guideline for the Treatment of Partients with Schizophrenia, Second Edition

  2004influential reference
• Clinical Pharmacokinetics of Levetiracetam

  2004influential reference
• Psychiatric adverse events during levetiracetam therapy

  2003cited by this paper
• Effects of lamotrigine and levetiracetam on seizure development in a rat amygdala kindling model.

  2003cited by this paper
• Interneuron Diversity series: Rhythm and mood in perisomatic inhibition.

  2003cited by this paper
• Dose-response effect of levetiracetam 1000 and 2000 mg/day in partial epilepsy.

  2002cited by this paper
• Levetiracetam Psychosis in Children with Epilepsy

  2001cited by this paper
• Efficacy and Tolerability of Levetiracetam 3000 mg/d in Patients with Refractory Partial Seizures: A Multicenter, Double‐Blind, Responder‐Selected Study Evaluating Monotherapy

  2000cited by this paper
• Levetiracetam. A review of its adjunctive use in the management of partial onset seizures.

  2000cited by this paper
• Adverse Effects of Antiepileptic Drugs

  2000cited by this paper
• Multicenter Double‐Blind, Randomized, Placebo‐Controlled Trial of Levetiracetam as Add‐On Therapy in Patients with Refractory Partial Seizures

  2000cited by this paper
• Evidence for altered trisynaptic circuitry in schizophrenic hippocampus.

  1999cited by this paper
• In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent.

  1999cited by this paper
• Resting cerebral glucose metabolism in first-episode and previously treated patients with schizophrenia relates to clinical features.

  1995cited by this paper
• Cognitive effects of a new pyrrolidine derivative (levetiracetam) in patients with epilepsy.

  1995cited by this paper
• Psychometric properties of the positive and negative syndrome scale (PANSS) in schizophrenia.

  1994cited by this paper
• The left medial temporal region and schizophrenia. A PET study.

  1992cited by this paper
• Patterns of Cerebral Blood Flow in Schizophrenia

  1992cited by this paper
• The positive and negative syndrome scale (PANSS) for schizophrenia.

  1987cited by this paper
• Concurrent and Predictive Validity of a Self-reported Measure of Medication Adherence

  1986cited by this paper
• A Rating Scale for Mania: Reliability, Validity and Sensitivity

  1978cited by this paper
• A RATING SCALE FOR DEPRESSION

  1960cited by this paper

• No citing papers are available for this paper.